February 2, 2016
In an alarming shakeup to the HIV/AIDS community, the U.S. Congress dropped annual budget language that allocated 10% of the National Institutes of Health (NIH) yearly funding towards HIV/AIDS research. The sudden reallocation of resources for HIV/AIDS research at the NIH represents a potentially massive impact on the foundational science that has led to the discovery of numerous groundbreaking treatments and creation of game-changing prevention strategies in the past 30 years of the epidemic. The loss of the 10% allocation is only one of the many mounting threats to HIV/AIDS research funding at NIH heading into 2016.
Join Treatment Action Group and the HIV Prevention Justice Alliance for a webinar discusses the role of the Office AIDS Research (OAR), how essential HIV research funded through NIH translates to treatments, programs, services and policy. Additionally, advocates will learn the landscape of NIH HIV/AIDS research priorities, how research impacts policy and programs, and concrete ways to mobilize on this urgent issue.
Carl Dieffenbach, Ph.D – Director of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID)
Jose Bauermiester, M.P.H., Ph.D – Director of the Center for Sexuality and Health Disparities (SexLab), University of Michigan School of Public Health
Mark Harrington – Executive Director, Treatment Action Group
Wendy Davis, Ed.D – Senior Manager and Senior Associate at Center for AIDS Research, Prevention Core, Johns Hopkins University Bloomberg School of Public Health
Kenyon Farrow – US and Global Policy Director, Treatment Action Group